Clinical Trials Logo

Ganglion Cysts clinical trials

View clinical trials related to Ganglion Cysts.

Filter by:
  • Completed  
  • Page 1 ·  Next »

NCT ID: NCT06177379 Completed - Clinical trials for Dorsal Root Ganglion

Magnetic Resonance Neurography Analysis of Healthy Human Thoracic Dorsal Root Ganglion

Start date: January 1, 2023
Phase:
Study type: Observational

Here, this study aimed to conduct magnetic resonance neurography (MRN) of the thoracic DRGs in a cohort of healthy individuals. The acquired images will be thoroughly analyzed utilizing 3D-slicer software. We expect to furnish crucial baseline anatomical data of thoracic DRGs in healthy subjects, provide an anatomical basis for clinical investigation and therapeutic interventions.

NCT ID: NCT06016816 Completed - Clinical trials for Anesthesia of Mucous Membrane

The Effect of Bilateral Sphenopalatine Ganglion Block on Postoperative Pain in Patients to be Subject to Septorhinoplasty Surgery

Start date: January 9, 2024
Phase: N/A
Study type: Interventional

The aim of this study is to examine the effects of bilateral sphenopalatine ganglion block on surgical conditions, hemodynamics, intraoperative and postoperative analgesic use, recovery characteristics, and postoperative pain during septorhinoplasty under general anesthesia. The study was planned as double-blind, randomized, controlled. 72 patients who will undergo septorhinoplasty surgery will be collected. (g power analysis was performed.) Evaluation of the effectiveness of bilateral sphenopalatine ganglion block was planned. Patients will be divided into 2 equal groups (36 patients). After the induction of general anesthesia, one group (Group: 1) will be administered 8mg dexamethasone and 10mg bupivacaine submucosal, the other group (group:2) will be administered 4 cc saline. aspects will be evaluated.

NCT ID: NCT05854537 Completed - Postoperative Pain Clinical Trials

Sphenopalatine Ganglion Block in Maxillofacial Surgeries

Start date: March 20, 2023
Phase: N/A
Study type: Interventional

Patients will be divided into 2 groups, 30 each. Group A will receive sphenopalatine ganglion block via a gauze soaked in local anesthetic introduced in the 2 nostrils then by local anesthetic injected by a cannula into both nostrils. Group B will undergo the same procedure, but normal saline will be used instead of the local anesthetic.

NCT ID: NCT05652179 Completed - Clinical trials for Stellate Ganglion Block

SGB Reduces the Incidence and Severity of CSA-AKI

Start date: January 10, 2023
Phase: N/A
Study type: Interventional

The incidence of acute kidney injury after cardiopulmonary bypass cardiac surgery is high, which increases postoperative mortality and is not conducive to the prognosis of patients. Stellate ganglion blocks increase renal blood flow, reduce inflammation and stress, and protect the heart muscle. In this study, stellate ganglion block was used to promote rapid recovery of kidney function after cardiopulmonary bypass cardiac surgery.

NCT ID: NCT05627895 Completed - Clinical trials for Basal-ganglia fMRI Neurofeedback

Brain Self-regulation for Parkinson's

Brain-REG
Start date: August 17, 2023
Phase:
Study type: Observational

To investigate feasibility of basal-ganglia regions as fMRI-neurofeedback targets in Parkinson's patients and evaluate self-regulation success

NCT ID: NCT05513209 Completed - Clinical trials for DECREASE POSTTONSILLECTOMY NAUSEA AND VOMITTING

Opioid Free Pterygopalatine Ganglion Block Based Multimodal Anesthesia for Tonsillectomy Operations

Start date: September 1, 2022
Phase: N/A
Study type: Interventional

intraoperative opioid administration versus intraoperative pterygopalatine ganglion block based opioid free anesthesia to compare outcomes such as postoperative administration of opioid rates of nausea and vomiting, Post Anesthesia Care Unit (PACU) length of stay

NCT ID: NCT05301387 Completed - Clinical trials for Post-Dural Puncture Headache

The Effect of Ganglion Sphenopalatine Block (GSP-block) Follow-Up

GSP-FOLLOW
Start date: November 26, 2021
Phase:
Study type: Observational

The purpose of this study is to evaluate the long term effects of the ganglion sphenopalatine block (GSP block) on postdural puncture headache.

NCT ID: NCT05269147 Completed - Clinical trials for Septum; Deviation, Congenital

Lidocaine Versus Bupivacaine for Sphenopalatine Ganglion Block

Start date: March 1, 2022
Phase: N/A
Study type: Interventional

The endoscopic septoplasty technique is one of the most frequently performed operations by otolaryngologists throughout the world. It is suggested that 86% of patients who undergo an endoscopic septoplasty would experience pain, and 75% of them suffer moderate to extreme levels of pain. Appropriate management of post-operative pain is a critical component of nasal surgery as it reduces perioperative morbidity, complications, hospital stay, and costs. The sphenopalatine ganglion (SPG) is located in the cranial section of the autonomous nervous system; it is connected with the brain stem and the central nervous system (CNS) and bears unique characteristics favorable for the treatment of many painful syndromes involving the face and head. Sphenopalatine ganglion block (SPGB), along with general anesthesia (GA), is one of the regional anesthetic techniques used to reduce the need for systemic analgesia and provides relative hypotension with controlled heart rate that may lead to a better surgical field for endoscopic surgery. In addition, SPGB appears to shorten hospital stays and reduce narcotic requirements in the recovery area. SPGB with bupivacaine delivered repetitively appears to decreased postoperative pain and more satisfaction with the surgery for patients. Also, Bupivacaine usage in nasal surgery provides better analgesia at least in the first 8 hours period and does not cause more bleeding. On the other hand, SPGB with lidocaine was found to decrease the need for additional analgesics in the postoperative period, increase patient satisfaction, decrease the length of hospital stay, and as a consequence, reduce the rate of secondary infections. However, no previous studies have demonstrated the superiority of one drug over the other when performing an intranasal SPG block. Aim of the work: To determine the efficacy of lidocaine versus bupivacaine for sphenopalatine ganglion block in patients undergoing endoscopic septoplasty.

NCT ID: NCT05099835 Completed - Clinical trials for Change From Baseline House-Brackmann

Ultrasound-Guided Stellate Ganglion Block With Botulinum

Start date: November 1, 2021
Phase: N/A
Study type: Interventional

the local stellate ganglion block with bupivacaine and corticosteroid treatment for acute peripheral facial nerve palsy in patients can induce hyperglycemia, and an alternative local therapy may be necessary and some time may ve ineffective. Our purpose in this study is to evaluate therapeutic effects of stellate ganglion block (SGB) Botulinum Toxin on referactory facial nerve palsy

NCT ID: NCT04892290 Completed - Clinical trials for Postdural Puncture Headache

Sphenopalatine Ganglion Block for Postdural Puncture Headache

Start date: December 1, 2019
Phase:
Study type: Observational

Background: Postdural puncture headache (PDPH), which is one of the complications of spinal anesthesia, is a condition that negatively affects the quality of life of patients, causes late mobilization and prolonged hospital stay. Sphenopalatine ganglion block (SGB) has created a minimally invasive, easy, and safe treatment alternative. Objective: Evaluating the effectiveness of topical SGB on PDPH treatment. Design: Retrospective observational study Setting: Single center tertiary level of care hospital study. The files of PDPH patients between Jan 2018 and Jan 2020 were scanned. Patients: PDPH patients aged 18-65 are included and any patients with primary/secondary headache history are excluded. Main outcome measures: Patients were divided into 2 groups. The group that given only conservative treatment was named as Group C, and the group of patients who had additionally been applied SGB was named as Group SGB. Headache severity was measured with Visual Analogue Scale (VAS) at the 1st,3rd, 12th and 24th hours of the treatment, in supine and upright position.